Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Recommendation of “Reduce” from Analysts

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) have earned a consensus recommendation of “Reduce” from the eight analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and seven have given a hold rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $24.00.

A number of analysts have recently issued reports on AMPH shares. Weiss Ratings cut shares of Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, April 10th. Piper Sandler restated a “neutral” rating and set a $21.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 11th. Wells Fargo & Company restated an “equal weight” rating and set a $19.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Thursday, May 14th. Jefferies Financial Group restated a “hold” rating and set a $22.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, April 21st. Finally, Barclays cut their target price on shares of Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating for the company in a research note on Wednesday, June 3rd.

Institutional Trading of Amphastar Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. FNY Investment Advisers LLC acquired a new stake in Amphastar Pharmaceuticals in the 3rd quarter worth about $26,000. Quarry LP bought a new position in Amphastar Pharmaceuticals in the 3rd quarter valued at about $32,000. Farther Finance Advisors LLC increased its holdings in Amphastar Pharmaceuticals by 46.3% in the 4th quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock valued at $37,000 after buying an additional 437 shares during the period. GAMMA Investing LLC increased its holdings in Amphastar Pharmaceuticals by 37.8% in the 4th quarter. GAMMA Investing LLC now owns 1,685 shares of the company’s stock valued at $45,000 after buying an additional 462 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Amphastar Pharmaceuticals by 24.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock valued at $60,000 after buying an additional 435 shares during the period. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH opened at $18.81 on Monday. The firm has a 50-day moving average of $19.97 and a 200-day moving average of $23.07. Amphastar Pharmaceuticals has a one year low of $16.65 and a one year high of $31.26. The company has a market cap of $829.33 million, a PE ratio of 11.33, a price-to-earnings-growth ratio of 3.70 and a beta of 0.91. The company has a debt-to-equity ratio of 0.79, a current ratio of 3.85 and a quick ratio of 2.82.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. The firm had revenue of $171.17 million during the quarter, compared to the consensus estimate of $173.46 million. As a group, equities analysts forecast that Amphastar Pharmaceuticals will post 2.41 earnings per share for the current year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.